Laleman Pharma
ActiveFinancials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 08-06-2026 at the NBB
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Staff
| Item | 31-12-2025 |
|---|---|
| Employees at the balance-sheet date | 1 |
| full-time | 0 |
| part-time | 1 |
| in full-time equivalents | 0.5 |
| Average over the year, in full-time equivalents | 0.1 |
| On a permanent contract | 1 |
| Joined | 1 |
| Left | 0 |
Source: social balance sheet in the 2025 annual accounts
Securities and guarantees
| Item | 2025 |
|---|---|
| Mortgages, amount registered | €27,500 |
| Mortgage mandates | €1.0m |
| Carrying value of the mortgaged assets | €854,914 |
| Pledge on the business | €357,500 |
Source: notes to the 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
| Item | 2025 |
|---|---|
| Tangible fixed assets | €1.1m |
| Intangible fixed assets | €200,000 |
| Depreciation and write-downs of the year | €210,335 |
Source: notes to the 2025 annual accounts (statement of fixed assets)
Subsidies and aid
Flemish government
2025 · 2 entries · €1,759 awarded · €1,759 paid| Line | 2025 |
|---|---|
| Remuneration, social security and pensions62 | €12,864 |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €210,335 |
| Other operating charges640/8 | €2,690 |
| Gross operating margin9900 | €232,565 |
| Operating profit (loss)9901 | €6,676 |
| Financial income75/76B | €1,565 |
| Recurring financial income75 | €1,565 |
| Financial charges65/66B | €46,074 |
| Recurring financial charges65 | €46,074 |
| Profit (loss) for the period before taxes9903 | -€37,832 |
| Profit (loss) for the period9904 | -€37,832 |
| Profit (loss) for the period to be appropriated9905 | -€37,832 |
| Line | 2025 | |
|---|---|---|
| Assets | ||
| Total assets20/58 | €1.4m | |
| Fixed assets21/28 | €1.1m | |
| Intangible fixed assets21 | €0.2m | |
| Tangible fixed assets22/27 | €1.0m | |
| Land and buildings22 | €0.9m | |
| Plant, machinery and equipment23 | €0.1m | |
| Current assets29/58 | €0.3m | |
| Stocks and contracts in progress3 | €0.1m | |
| Stocks30/36 | €0.1m | |
| Amounts receivable within one year40/41 | €0.04m | |
| Trade receivables40 | €0.04m | |
| Cash at bank and in hand54/58 | €0.1m | |
| Deferred charges and accrued income490/1 | €0.001m | |
| Equity and liabilities | ||
| Total equity and liabilities10/49 | €1.4m | |
| Equity10/15 | €0.2m | |
| Contributions10/11 | €0.3m | |
| Profit (loss) carried forward14 | -€0.04m | |
| Amounts payable17/49 | €1.2m | |
| Amounts payable after more than one year17 | €0.9m | |
| Financial debts170/4 | €0.9m | |
| Amounts payable within one year42/48 | €0.4m | |
| Current portion of amounts payable after more than one year42 | €0.05m | |
| Trade debts44 | €0.03m | |
| Suppliers440/4 | €0.03m | |
| Taxes, remuneration and social security45 | €0.01m | |
| Taxes450/3 | €0.006m | |
| Remuneration and social security454/9 | €0.006m | |
| Other amounts payable47/48 | €0.3m | |
| Line | 2025 |
|---|---|
| Profit (loss) for the period9904 | -€37,832 |
| + Depreciation and write-downs630 | €210,335 |
| Operating cash flow (approximation) | €172,502 |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 1,271 companies had the same profile as Laleman Pharma has now. Two years later, 93.5% were still going and 4.1% had gone bankrupt.
- Micro
- 2 to 5 years old
- solvency 10 to 30%
- a small loss
Another 0.3% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of Laleman Pharma itself: 1.0% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,271 companies, not a prediction for Laleman Pharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (1)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 08-06-2026 | 2026-00144962 |